The frequency of metabolic syndrome in schizoprenia patients using antipsychotic medication and related factors;Antipsikotik kullanan şizofreni hastalarında metabolik sendrom sıklıǧı ve ilişkili etmenleri

Yeni Symposium

Volumn 49, Issue 2, 2011, Pages 67-76

  Güveli, Hülya ^a   Cem Ilnem, M ^a   Yener, Ferhan ^a   Karamustafalioǧlu, Nesrin ^a   Ipekçioǧlu, Derya ^a   Abanoz, Zuhal ^b  

^a Bakirköy Ruh ve Sinir Hastaliklari Hastanesi   (Turkey)

^b Batman Devlet Hastânesi   (Turkey)

Author keywords

Antipsychotics; Metabolic syndrome; Schizophrenia

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT; OUTPATIENT DEPARTMENT; PREVALENCE; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; WAIST CIRCUMFERENCE;

EID: 79958101283     PISSN: 13008773     EISSN: 13044591     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and classification of diabetes melitus pro its complications, pt 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med; 15: 539-553.
2. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. (1999) The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry; 60: 215-220.
3. Allison DB, Mentore JL, Heo M, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry; 156: 1686-1696.
4. Bakos CD, Berecz R, Degrell I (2004) Effect of atypical antipsychotics on metabolism. Neuropsyhchopharma Col Hung; 6: 86-89.
5. Böke Ö (2006) Şizofreni Hastalar{dotless}nda Metabolik Sendrom. 42.Ulusal Psikiyatri Kongresi Özet Kitab{dotless}.
6. Cerit C, Özten E, Yildiz M. (2007) Şizofreni Hastalar{dotless}nda Metabolik Sendrom S{dotless}kl{dotless}ǧ{dotless} ve {dotless}liflkili Etmenler. Türk Psikiyatri Dergisi,18(3)
7. Cohn T, Prud'homme D, Streiner D ve ark. (2004) Characterizing coronary heart desease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry, 49: 753-760.
8. Coodin S (2001) Body mass index in persons with schizophrenia. Can J Psychiatry; 46: 549-555.
9. De Hert MA, Winkel RV, Eyck DV ve ark. (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizoph Res; 83: 87-93.
10. De Hert M, van Winkel R, Van Eyck D, ve ark. (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health; 27: 2-14.
11. De Hert M, van Winkel R, Van Eyck D, ve ark. (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health; 27: 2-14.
12. Ford ES, Giles WH, Dietz WH, et al. (2002) Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA; 287: 356-359.
13. Grundy SM (1998) Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol; 81: 18-25.
14. Grundy SM, Brewer B, Cleeman JL, et al. (2004) Def{dotless}nition of metabolic syndrome: report of the National Heart, Lung And Blood nstitude/American Heart Association Conference on scientific issues related to definition. Circulation; 109:433-438.
15. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R (1998) Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry; 59: 294-299.
16. Hagg S, Lindblom Y, Mjörndal T, et al. (2006) High prevalence of the metabolic sydrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol; 21: 93-98.
17. Haupt D, Newcomer J (2001) Hyperglycemia and antipsychotic medications. J Clin Psychiatry; 62 (suppl 27): 15-26.
18. Heiskanen T, Niskanen L, Lytikainen L, et al. (2003) Metabolic Syndrome In Patients With Schizophrenia. J Clin Psychiatry; 64: 575-579.
19. Isomaa B, Almgren P, Tuomi T, et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care; 24: 683-689.
20. Kabinoff GS, Toalson PA, Healey KM, McGuire HC, Hay DP, (2003) Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths. Prim Care Companion J Clin Psychiatry; 5: 6-14.
21. Kato M, Currier B, Gomez C et al. Prevalence of metabolic syndrome in Hispanic and Non-Hispanic patients with schizophrenia (2004) Prim Care Companion J Clin Psychiatry; 6: 74-77.
22. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, Mc Evoy JP, et al. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atiypical antipsychotics. Am J Psychiatry; 160: 290-296.
23. Meduna L, Gerty F, Urse V (1942) Biochemical disturbances in mental disorders. Arch Neurol Psychiatry; 47: 38-52.
24. McEvoy JP, Meyer JM, Goff DC, et al. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res; 80: 19-32.
25. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther.; 251: 238-246.
26. Metabolik Sendrom Araşt{dotless}rma Grubu (2004) METSAR sonuçlar{dotless}. XX. Ulusal Kardiyoloji Kongresi, Antalya.
27. Nasrallah HA, Newcomer JW (2004) Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol; 24(suppl 1): 7-14.
28. Newman SC, Bland RC (1991) Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry; 36: 239-245.
29. Onat A, Sansoy V (2002) Halk{dotless}m{dotless}zda Koroner Hastal{dotless}ǧ{dotless}n Baflsuçlusu Metabolik Sendrom: S{dotless}kl{dotless}ǧ{dotless}, Unsurlar{dotless}, Koroner Risk ile {dotless}liflkisi ve Yüksek Risk Kriterleri. Türk Kardiyol Dern Arafl; 30: 8-15
30. Özbakkaloǧlu M, Demirci C (2003) SSK Tepecik Hastânesi Dergisi; 13: 121-127.
31. Raphael T, Parsons I (1921) Blood sugar studies in demantia praecox and manic depressive insanity. Arch Neurol Psychiatry; 5: 687-709.
32. Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry; 160: 284-289.
33. Saari KM, Lindeman SM, Viilo KM et al. (2005) A4-Fold risk of metabolic syndrome in patients with schizophrenia: The northern Finland 1966 Birth cohort study. J Clin Psychiatry;66: 559-563.
34. Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K (1984) Decreased concentration of high density lipoprotein cholesterol in schizophrenic patients treated with phenothiazines. Atherosclerosis; 51: 163-169.
35. Toalson P, Ahmed S, Hardy T, Kabinoff G (2004) The Metabolic Syndrome in Patients With Severe Mental Illnesses. Prim Care Companion J Clin Psychiatry; 6: 152-158.
36. Vural M (2007) Şizofreni Ve Bipolar Affektif Bozukluk Hastalar{dotless}nda Antipsikotik {dotless}laç Kullan{dotless}m{dotless} {dotless}le Metabolik Sendrom Ve Diǧer Metabolik Süreçlerin {dotless}liflkisinin {dotless}ncelenmesi. Uzmanl{dotless}k Tezi, {dotless}stanbul: Haydarpafla Eǧitim Ve Araflt{dotless}rma Hastânesi, Psikiyatri Bölümü.
37. Yazici MK, Yaǧcioǧlu AEA, Ertuǧrul A. et al. (2005) The prevalence of metabolic syndrome in schizophrenic patients: a preliminary report. Eur Neuropsychopharmacol; 15: 520-521.
38. Yip P, Facchini FS, Reaven GM (1998) Resistance to insulin mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab.;83: 2773-2776. Abstract.